Sign In
Buy JJSF
$75.77
-0.360 (-0.473%)
At Close: Jun 03, 2026
Johnson&Johnson blåser förbi uppskattningar för tredje kvartalet | Invezz
11:24pm, Tuesday, 13'th Oct 2020
J&J rapporterar £16,27 miljarder i omsättning och £1,70 justerat resultat per kvartal. J&J höjde sin vägledning för årlig justerad vinst och intäkter.
Covid-19: What you need to know today
11:20pm, Tuesday, 13'th Oct 2020
Pauses, and even holds, are common in the vaccine development process. But this isn’t just any ordinary vaccine. It is a vaccine for the coronavirus disease, which has infected 38 million and killed
J&J halts vaccine trial due to unexplained illness
09:00pm, Tuesday, 13'th Oct 2020
NEW JERSEY • Johnson & Johnson halted clinical trials of its Covid-19 vaccine after a participant fell ill, the second time that a front runner developer has paused testing in the race to create a v
J&J tardará días en retomar pruebas de vacuna por participante enfermo
08:39pm, Tuesday, 13'th Oct 2020
Mathai Mammen explicó que debido a que el estudio es ciego, la compañía aún no sabía si la persona enferma había recibido la vacuna o un placebo.
Johnson & Johnson supera le stime di Wall Street nel Q3 | Invezz
07:59pm, Tuesday, 13'th Oct 2020
Johnson & Johnson supera le stime di Wall Street nel Q3 e registra £16,27 miliardi di entrate e £1,70 di EPS rettificato nel Q3.
Johnson & Johnson supera las estimaciones de Wall Street en el tercer trimestre | Invezz
06:43pm, Tuesday, 13'th Oct 2020
Johnson & Johnson (NYSE: JNJ) publicó el martes su informe de ganancias para el tercer trimestre fiscal que superó las estimaciones de los analistas de ganancias e ingresos. La compañía atribuyó
U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns
06:36pm, Tuesday, 13'th Oct 2020
The ACTIV-3 trial is one of several ongoing trials that are part of an NIH program to accelerate the development of vaccine treatments.
Johnson & Johnson blows past Wall Street estimates in the third quarter.
06:01pm, Tuesday, 13'th Oct 2020
Johnson & Johnson blows past Wall Street estimates in the third quarter. The U.S. multinational raised its guidance for annual adjusted EPS & revenue.
J&J Hopes Covid-19 Vaccine Trial Will Restart Shortly | MarketScreener
05:53pm, Tuesday, 13'th Oct 2020Johnson & Johnson beats 3Q profit views, hikes 2020 forecast
05:21pm, Tuesday, 13'th Oct 2020
Johnson & Johnson posted revenue of $21.08 billion in the quarter.Amid the COVID-19 pandemic, J&J still managed to boost sales of its prescription drugs 5% to $11.42 billion, just over half its entire
J&J says review of illness that led to pause of coronavirus vaccine trial could take days
03:27pm, Tuesday, 13'th Oct 2020
Johnson & Johnson said today it would take a few days at least to hear from a safety monitoring panel about its review of the company's late-stage Covid-19 vaccine trial after announcing that the larg
J&J Beat Earnings Forecasts. Why the Stock Is Down.
03:12pm, Tuesday, 13'th Oct 2020
The pharmaceutical company raised its financial forecasts as it reported its third-quarter results.
The U.S. death toll from the coronavirus-borne illness COVID-19 climbed above 215,000 on Tuesday, after President Donald Trump returned to the campaign trail...
The pause in Johnson & Johnson’s COVID-19 vaccine trial justifies why Big Pharma isn’t eager to rush to market
02:37pm, Tuesday, 13'th Oct 2020
Pharmaceutical companies will resist pressure from politicians such as U.S. President Donald Trump to speed up the vaccine trial and approval process.
